Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Jacot

Showing results (131-140 of 196) with videos related to

Pageof 20
Sort By:
The Oncologist|June 27, 2015
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyJoseph Gligorov, Xavier B Pivot, William Jacot, et al.
British Journal of Cancer|December 4, 2019
Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samplesAlexandre Ho-Pun-Cheung, Hervé Bazin, Florence Boissière-Michot, et al.
Clinical Chemistry|July 27, 2020
Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast CancerWilliam Jacot, Martine Mazel, Caroline Mollevi, et al.
Neuro-Oncology|May 24, 2022
A comprehensive profiling of the immune microenvironment of breast cancer brain metastasesGaia Griguolo, Anna Tosi, Maria Vittoria Dieci, et al.
Genome Medicine|April 26, 2023
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancersKatherine E Hutchinson, Jessica W Chen, Heidi M Savage, et al.
Breast Cancer Research : BCR|June 10, 2026
Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohortStéphane Vignot, Youenn Drouet, Antonio Di Meglio, et al.
British Journal of Cancer|November 17, 2023
Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancerZahra Eslami-S, Luis Enrique Cortés-Hernández, Léa Sinoquet, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 24, 2024
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patientsAlicja Puszkiel, Florence Dalenc, Naïma Tafzi, et al.
Molecular Oncology|March 9, 2023
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomesJessica W Chen, William Jacot, Javier Cortés, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2025
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohortFanny Bouteiller, Sophie Gourgou, Michaël Bringuier, et al.
Pageof 20

Showing results (131-140 of 196) with videos related to

Sort By:
Pageof 20
The Oncologist|June 27, 2015
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyJoseph Gligorov, Xavier B Pivot, William Jacot, et al.
British Journal of Cancer|December 4, 2019
Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samplesAlexandre Ho-Pun-Cheung, Hervé Bazin, Florence Boissière-Michot, et al.
Clinical Chemistry|July 27, 2020
Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast CancerWilliam Jacot, Martine Mazel, Caroline Mollevi, et al.
Neuro-Oncology|May 24, 2022
A comprehensive profiling of the immune microenvironment of breast cancer brain metastasesGaia Griguolo, Anna Tosi, Maria Vittoria Dieci, et al.
Genome Medicine|April 26, 2023
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancersKatherine E Hutchinson, Jessica W Chen, Heidi M Savage, et al.
Breast Cancer Research : BCR|June 10, 2026
Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohortStéphane Vignot, Youenn Drouet, Antonio Di Meglio, et al.
British Journal of Cancer|November 17, 2023
Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancerZahra Eslami-S, Luis Enrique Cortés-Hernández, Léa Sinoquet, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 24, 2024
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patientsAlicja Puszkiel, Florence Dalenc, Naïma Tafzi, et al.
Molecular Oncology|March 9, 2023
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomesJessica W Chen, William Jacot, Javier Cortés, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2025
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohortFanny Bouteiller, Sophie Gourgou, Michaël Bringuier, et al.
Pageof 20